CTLA 4 News and Research

RSS

Seeing the Unexpected: Regulatory T Cells and Basophils

Dr. Jagadeesh Bayry from INSERM discusses his recent research in the field of immunology, and how T regulatory cells activate, rather than suppress, basophils.

4 Jul 2018

Study finds distinct exhausted T cells that could have implications for fighting different diseases

The battle between the human immune system and long-term, persisting infections and other chronic diseases such as cancer results in a prolonged stalemate

16 May 2018

Cancer Center at BIDMC announces launch of new Immunotherapy Institute

The Cancer Center at Beth Israel Deaconess Medical Center today announced the launch of a new clinical and research institute that will build on BIDMC's long history of leadership in immunotherapy and cell therapeutics.

3 May 2018

MD Anderson research provides insight into memory T cell development and disease relapse

Just like people, some T cells have excellent memories. These subtypes known as memory T cells may explain why some immunotherapies are more effective than others and potentially lead to researchers designing more effective studies using combination checkpoint blockade treatments, according to experts at The University of Texas MD Anderson Cancer Center.

16 Apr 2018

Immunotherapy combination increases overall survival in people with kidney cancer, study shows

Treating people with advanced metastatic kidney cancer using a combination of the immunotherapy drugs nivolumab (Opdivo) and ipilimumab (Yervoy) significantly increased overall survival versus treatment with sunitinib (Sutent) alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center that were reported today in the New England Journal of Medicine.

22 Mar 2018

Johns Hopkins researchers invent new class of immunotherapy drugs to fight cancer

Johns Hopkins researchers have invented a new class of cancer immunotherapy drugs that are more effective at harnessing the power of the immune system to fight cancer.

2 Mar 2018

Efficacy of cancer immunotherapy increased by deactivating tumor defence mechanism

Novel bifunctional immunotherapeutic agents have been developed that, as well as deactivating key immune checkpoints,deactivate the tumor's protective response.

23 Feb 2018

Researchers explore new combination approach to treat high-risk soft-tissue sarcomas

University of Maryland School of Medicine researchers are investigating a new approach to treat high-risk soft-tissue sarcomas by combining two immunotherapy drugs with radiation therapy to stimulate the immune system to destroy the main tumor as well as leftover microscopic cancer cells that may seed other tumors.

20 Sep 2017

Combination immunotherapy as second or third line treatment of mesothelioma shows promising results

Combination immunotherapy as second or third line treatment extends overall survival to at least 15 months in patients with pleural malignant mesothelioma, according to late-breaking results from the MAPS2 trial presented today at the ESMO 2017 Congress in Madrid.

11 Sep 2017

Simultaneous treatment with anti-PD1 and anti-OX40 cancer therapies may have detrimental effect

Concurrent administration of the T-cell stimulating anti-OX40 antibody and the immune checkpoint inhibitor anti-PD1 antibody attenuated the effect of anti-OX40 and resulted in poor treatment outcomes in mice.

28 Aug 2017

Study: Response to combination immunotherapy in melanoma depends on proportion of immune cells

Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco researchers joined by physicians from UCSF Health.

20 Jul 2017

MGH researchers identify novel mechanism behind resistance to angiogenesis inhibitors

A Massachusetts General Hospital research team has identified a novel mechanism behind resistance to angiogenesis inhibitors - drugs that fight cancer by suppressing the formation of new blood vessels.

14 Jul 2017

Proteins impeding antitumor immunity could be 'Achilles heel' of some cancers

By comparing variations in protein expression in tumor samples from a single melanoma patient, researchers from the Johns Hopkins Bloomberg~Kimmel Institute and the Memorial Sloan-Kettering Cancer Center say their findings have the potential to reveal some of the mechanisms underlying response or resistance to immunotherapy drugs.

28 Jun 2017

Combination approach holds potential for treating lung cancer patients

An emerging approach for cancer treatment seeks to combine radiation therapy with immune checkpoint inhibitors to more effectively control tumors in the chest with an acceptable risk of severe treatment-related side effects.

17 Mar 2017

Evolution of immuno-oncology

Immuno-oncology did not exist four years ago, it's a term coined by Dr. Axel Hoos, Head of the newly defined immuno-oncology department at GSK. He is also Senior Vice President Therapeutic Area (TA) and Head for Oncology R&D. Previously, it was referred to as cancer immunotherapy, but now it is called immuno-oncology (IO).

13 Mar 2017

CTLA 4 News and Research

Seeing the Unexpected: Regulatory T Cells and Basophils

Study finds distinct exhausted T cells that could have implications for fighting different diseases

Cancer Center at BIDMC announces launch of new Immunotherapy Institute

MD Anderson research provides insight into memory T cell development and disease relapse

Immunotherapy combination increases overall survival in people with kidney cancer, study shows

Johns Hopkins researchers invent new class of immunotherapy drugs to fight cancer

Efficacy of cancer immunotherapy increased by deactivating tumor defence mechanism

Researchers explore new combination approach to treat high-risk soft-tissue sarcomas

Combination immunotherapy as second or third line treatment of mesothelioma shows promising results

Simultaneous treatment with anti-PD1 and anti-OX40 cancer therapies may have detrimental effect

Study: Response to combination immunotherapy in melanoma depends on proportion of immune cells

MGH researchers identify novel mechanism behind resistance to angiogenesis inhibitors

Proteins impeding antitumor immunity could be 'Achilles heel' of some cancers

Combination approach holds potential for treating lung cancer patients

Evolution of immuno-oncology

Combination of drugs amplifies kill rates of brain cancer tumours in mice

Northwestern Medicine investigators to lead clinical trial for people with rare cancers

Immune checkpoint cancer therapies may cause rare cardiac side effects linked to unexpected immune response

Immune checkpoint inhibitor as adjuvant therapy improves overall survival in patients with stage III melanoma

Approval of PD-1 inhibitor scratches surface of potential immunotherapies in recurrent HNSCC

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News